JP2013543492A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013543492A5 JP2013543492A5 JP2013530810A JP2013530810A JP2013543492A5 JP 2013543492 A5 JP2013543492 A5 JP 2013543492A5 JP 2013530810 A JP2013530810 A JP 2013530810A JP 2013530810 A JP2013530810 A JP 2013530810A JP 2013543492 A5 JP2013543492 A5 JP 2013543492A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- composition according
- buffer
- carbetocin
- antioxidant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 19
- 239000000872 buffer Substances 0.000 claims 4
- NSTRIRCPWQHTIA-DTRKZRJBSA-N carbetocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSCCCC(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(OC)C=C1 NSTRIRCPWQHTIA-DTRKZRJBSA-N 0.000 claims 4
- 229960001118 carbetocin Drugs 0.000 claims 4
- 108700021293 carbetocin Proteins 0.000 claims 4
- 239000003963 antioxidant agent Substances 0.000 claims 3
- 230000003078 antioxidant effect Effects 0.000 claims 3
- 239000007788 liquid Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 208000034423 Delivery Diseases 0.000 claims 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 2
- 208000032843 Hemorrhage Diseases 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 230000000740 bleeding effect Effects 0.000 claims 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 2
- 239000007951 isotonicity adjuster Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229930182817 methionine Natural products 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000003169 placental effect Effects 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid group Chemical group C(CCC(=O)O)(=O)O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims 2
- 230000009677 vaginal delivery Effects 0.000 claims 2
- 208000004998 Abdominal Pain Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 208000008035 Back Pain Diseases 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- 206010010774 Constipation Diseases 0.000 claims 1
- 206010057671 Female sexual dysfunction Diseases 0.000 claims 1
- 206010061974 Gastrointestinal obstruction Diseases 0.000 claims 1
- 206010021718 Induced labour Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 1
- 206010057672 Male sexual dysfunction Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000018525 Postpartum Hemorrhage Diseases 0.000 claims 1
- 208000036064 Surgical Blood Loss Diseases 0.000 claims 1
- 206010046763 Uterine atony Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 208000034158 bleeding Diseases 0.000 claims 1
- 239000007853 buffer solution Substances 0.000 claims 1
- 239000006172 buffering agent Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000007979 citrate buffer Substances 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 230000006651 lactation Effects 0.000 claims 1
- 208000004396 mastitis Diseases 0.000 claims 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims 1
- 230000036407 pain Effects 0.000 claims 1
- 239000008363 phosphate buffer Substances 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 150000003890 succinate salts Chemical group 0.000 claims 1
- 239000001384 succinic acid Substances 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10251690.3 | 2010-09-30 | ||
| EP10251690 | 2010-09-30 | ||
| PCT/IB2011/002394 WO2012042371A2 (en) | 2010-09-30 | 2011-09-29 | Pharmaceutical composition |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016215212A Division JP6250770B2 (ja) | 2010-09-30 | 2016-11-02 | 医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013543492A JP2013543492A (ja) | 2013-12-05 |
| JP2013543492A5 true JP2013543492A5 (enExample) | 2014-07-31 |
| JP6038797B2 JP6038797B2 (ja) | 2016-12-07 |
Family
ID=43478408
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013530810A Active JP6038797B2 (ja) | 2010-09-30 | 2011-09-29 | 医薬組成物 |
| JP2016215212A Active JP6250770B2 (ja) | 2010-09-30 | 2016-11-02 | 医薬組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016215212A Active JP6250770B2 (ja) | 2010-09-30 | 2016-11-02 | 医薬組成物 |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US9566311B2 (enExample) |
| EP (5) | EP3222272B1 (enExample) |
| JP (2) | JP6038797B2 (enExample) |
| KR (2) | KR101919119B1 (enExample) |
| CN (4) | CN103124554A (enExample) |
| AU (1) | AU2011309762B2 (enExample) |
| BR (2) | BR112013007362B1 (enExample) |
| CA (1) | CA2812510A1 (enExample) |
| CY (2) | CY1119245T1 (enExample) |
| DK (4) | DK4374878T3 (enExample) |
| ES (4) | ES2637988T3 (enExample) |
| FI (1) | FI4374878T3 (enExample) |
| HR (3) | HRP20211969T1 (enExample) |
| HU (4) | HUE056835T2 (enExample) |
| IL (3) | IL225238B (enExample) |
| JO (3) | JO3400B1 (enExample) |
| LT (3) | LT4374878T (enExample) |
| MX (3) | MX390779B (enExample) |
| NZ (1) | NZ609719A (enExample) |
| PL (4) | PL4374878T3 (enExample) |
| PT (4) | PT3222272T (enExample) |
| RS (3) | RS62873B1 (enExample) |
| RU (2) | RU2737264C2 (enExample) |
| SI (4) | SI3222272T1 (enExample) |
| SM (3) | SMT202200034T1 (enExample) |
| TW (6) | TWI650134B (enExample) |
| WO (1) | WO2012042371A2 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070224184A1 (en) * | 2006-02-22 | 2007-09-27 | The Research Foundation Of The State University Of New York | Method for treating cellulite |
| UA117912C2 (uk) * | 2012-05-08 | 2018-10-25 | Ділафор Аб | Застосування гепарину або гепарансульфату для лікування післяпологової кровотечі (ппк) |
| JP6599447B2 (ja) * | 2014-09-19 | 2019-10-30 | フェリング ベスローテン フェンノートシャップ | プラダー・ウィリー症候群を治療する方法 |
| ES2690140T3 (es) | 2014-10-01 | 2018-11-19 | Oxytone Bioscience B.V. | Unidad de dosificación farmacéutica sólida de desintegración oral que contiene una sustancia de control del parto |
| PL3200764T3 (pl) | 2014-10-01 | 2020-12-28 | Oxytone Bioscience B.V. | Rozpadająca się w jamie ustnej stała farmaceutyczna jednostka dawkowania zawierająca substancję kontrolującą poród |
| SG11201705591PA (en) | 2015-01-07 | 2017-08-30 | Trigemina Inc | Magnesium-containing oxytocin formulations and methods of use |
| WO2016162819A1 (en) * | 2015-04-07 | 2016-10-13 | Lupin Limited | Stable aqueous pharmaceutical composition of anti-tnf alpha antibody |
| HRP20250215T1 (hr) | 2016-04-12 | 2025-06-20 | Tonix Pharma Limited | Formulacije oksitocina koje sadrže magnezij i postupci upotrebe |
| CN107773531B (zh) * | 2016-08-31 | 2021-05-04 | 成都倍特药业股份有限公司 | 一种马来酸麦角新碱注射液 |
| CN108236601B (zh) * | 2016-12-23 | 2020-04-17 | 深圳翰宇药业股份有限公司 | 一种稳定的含卡贝缩宫素的阴道给药的药用组合物及其制备方法 |
| WO2019030412A1 (en) * | 2017-08-11 | 2019-02-14 | Ferring B.V. | PROCESS FOR PRODUCING PHARMACEUTICAL PREPARATION |
| GB201721846D0 (en) * | 2017-12-22 | 2018-02-07 | Arecor Ltd | Novel composition |
| JP2021515005A (ja) | 2018-03-01 | 2021-06-17 | トライジェミナ， インコーポレイテッド | 標識オキシトシンならびに製造および使用の方法 |
| CN108721598B (zh) * | 2018-07-03 | 2020-06-05 | 北京市新里程医药科技有限公司 | 一种缩宫素原料的制备方法及其药物组合物和制剂 |
| CN114288253B (zh) | 2018-09-20 | 2024-04-02 | 阿卡蒂亚药品公司 | 稳定的鼻内卡贝缩宫素制剂 |
| KR20210062648A (ko) | 2018-09-20 | 2021-05-31 | 레보 테라퓨틱스 인코포레이티드 | 카르베토신 완제의약품 및 이를 제조하는 방법 |
| CN109745544B (zh) * | 2018-11-23 | 2024-11-08 | 南京新百药业有限公司 | 稳定的缩宫素药物组合物及其制备方法 |
| CN113453661A (zh) * | 2018-12-21 | 2021-09-28 | 艾瑞克有限公司 | 新组合物 |
| WO2020137880A1 (ja) * | 2018-12-27 | 2020-07-02 | 国立大学法人北海道大学 | オキシトシン誘導体及びその使用 |
| CA3141488A1 (en) | 2019-05-22 | 2020-11-26 | Biovie Inc. | Formulations of terlipressin |
| CN110308222A (zh) * | 2019-07-17 | 2019-10-08 | 武汉赛沃医药科技有限公司 | 一种卡贝缩宫素原料药有关物质检测方法 |
| CN110403904A (zh) * | 2019-07-26 | 2019-11-05 | 翔宇药业股份有限公司 | 卡贝缩宫素注射液及其应用 |
| CN110237230A (zh) * | 2019-07-31 | 2019-09-17 | 南京康舟医药科技有限公司 | 一种卡贝缩宫素药物组合物及其制备方法 |
| US20220313774A1 (en) | 2019-11-04 | 2022-10-06 | Ferring B.V. | Intranasal administration of merotocin for improving lactation |
| CN111012739A (zh) * | 2019-12-04 | 2020-04-17 | 长春圣金诺生物制药有限公司 | 一种可以常温储存的含卡贝缩宫素及稳定剂的注射液 |
| AU2022242768A1 (en) | 2021-03-26 | 2023-10-19 | Centre Hospitalier Universitaire De Toulouse | Treatment of dysphagia |
| CN114191388B (zh) * | 2021-12-27 | 2023-06-09 | 苏州天马医药集团天吉生物制药有限公司 | 一种卡贝缩宫素制剂的制备方法 |
| CN114712483B (zh) * | 2022-05-12 | 2023-09-29 | 成都倍特药业股份有限公司 | 一种麦角新碱缩宫素复方注射液及其制备方法和用途 |
| WO2024211393A2 (en) | 2023-04-04 | 2024-10-10 | Tulex Pharmaceuticals Inc. | Desmopressin oral compositions |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5482931A (en) * | 1993-06-29 | 1996-01-09 | Ferring Ab | Stabilized pharmaceutical peptide compositions |
| CN1109558A (zh) * | 1994-11-07 | 1995-10-04 | 马文亮 | 装有压力表的双管气筒 |
| SE9604341D0 (sv) * | 1996-11-26 | 1996-11-26 | Ferring Bv | Hepta-peptide oxytocin analogue |
| DE69736140T2 (de) | 1997-11-18 | 2007-04-19 | Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. | Pharmazeutische injizierbare Lösungen, die Paracetamol und Kombinationen aus Paracetamol mit anderen Aktivsubstanzen enthalten |
| US6333313B1 (en) | 1998-10-29 | 2001-12-25 | Board Of Regents, The University Of Texas System | Clinical use of oxytocin alone or in combination to treat bone disorders |
| US20070032410A1 (en) | 2000-01-11 | 2007-02-08 | Atossa Healthcare, Inc. | Compositions and methods for the treatment of psychiatric disorders |
| US6894026B1 (en) * | 2000-01-11 | 2005-05-17 | Atossa Healthcare, Inc. | Long-acting oxytocin analogues for the treatment and prevention of breast cancer and psychiatric disorders |
| JP2001233787A (ja) | 2000-02-04 | 2001-08-28 | Patents Exploitation Co Bv | 小・中サイズのペプチド含有薬学的組成物 |
| AT409081B (de) | 2000-02-16 | 2002-05-27 | Gebro Pharma Gmbh | Stabile, nasal, oral oder sublingual anwendbare pharmazeutische zubereitung |
| ATE556591T1 (de) | 2001-11-08 | 2012-05-15 | Abbott Biotherapeutics Corp | Stabile pharmazeutische flüssigformulierung von igg-antikörpern |
| DE60333857D1 (de) | 2002-10-03 | 2010-09-30 | Neuropharmacology Services Llc | Oxytocin zur Behandlung von Autismus und Asperger-Syndrom |
| ATE424215T1 (de) | 2003-01-08 | 2009-03-15 | Novartis Vaccines & Diagnostic | Stabilisierte wässrige zusammensetzungen mit gewebefaktorinhibitor (tfpi) oder gewebefaktorinhibitor-variante |
| CN1938040A (zh) | 2003-03-05 | 2007-03-28 | Pr药品有限公司 | 缩宫素控释制剂及其应用方法 |
| GT200600031A (es) * | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
| WO2008150305A1 (en) * | 2007-06-07 | 2008-12-11 | Nastech Pharmaceutical Company Inc. | Intranasal carbetocin formulations and methods for the treatment of autism |
| WO2009005351A1 (en) | 2007-07-02 | 2009-01-08 | Sime Darby Malaysia Berhad | Vegetable fat blend and edible products containing such a fat blend |
| ES2319054B1 (es) | 2007-08-06 | 2010-02-12 | Gp Pharm S.A. | Composicion farmaceutica oral de desmopresina. |
| SI2260053T1 (sl) * | 2008-03-31 | 2014-08-29 | Ferring Bv | Analogi oksitocina |
| CN102281865B (zh) * | 2008-10-15 | 2017-04-05 | 精达制药公司 | 高浓缩药物颗粒、制剂、混悬剂及其应用 |
-
2011
- 2011-09-28 JO JOP/2011/0297A patent/JO3400B1/ar active
- 2011-09-29 CA CA2812510A patent/CA2812510A1/en not_active Abandoned
- 2011-09-29 MX MX2016005537A patent/MX390779B/es unknown
- 2011-09-29 ES ES11776530.5T patent/ES2637988T3/es active Active
- 2011-09-29 EP EP17169328.6A patent/EP3222272B1/en active Active
- 2011-09-29 CN CN2011800464547A patent/CN103124554A/zh active Pending
- 2011-09-29 TW TW104135841A patent/TWI650134B/zh not_active IP Right Cessation
- 2011-09-29 PT PT171693286T patent/PT3222272T/pt unknown
- 2011-09-29 BR BR112013007362-4A patent/BR112013007362B1/pt active IP Right Grant
- 2011-09-29 AU AU2011309762A patent/AU2011309762B2/en active Active
- 2011-09-29 RS RS20220052A patent/RS62873B1/sr unknown
- 2011-09-29 TW TW109142907A patent/TWI750934B/zh active
- 2011-09-29 EP EP24166417.6A patent/EP4374878B1/en active Active
- 2011-09-29 JP JP2013530810A patent/JP6038797B2/ja active Active
- 2011-09-29 WO PCT/IB2011/002394 patent/WO2012042371A2/en not_active Ceased
- 2011-09-29 CN CN201510212609.XA patent/CN104906032A/zh active Pending
- 2011-09-29 LT LTEP24166417.6T patent/LT4374878T/lt unknown
- 2011-09-29 EP EP21192651.4A patent/EP3936117A1/en active Pending
- 2011-09-29 DK DK24166417.6T patent/DK4374878T3/da active
- 2011-09-29 RS RS20170827A patent/RS56220B1/sr unknown
- 2011-09-29 EP EP11776530.5A patent/EP2621468B1/en active Active
- 2011-09-29 HU HUE17169328A patent/HUE056835T2/hu unknown
- 2011-09-29 MX MX2013003365A patent/MX352949B/es active IP Right Grant
- 2011-09-29 SM SM20220034T patent/SMT202200034T1/it unknown
- 2011-09-29 SI SI201132022T patent/SI3222272T1/sl unknown
- 2011-09-29 DK DK17169301.3T patent/DK3246018T3/da active
- 2011-09-29 ES ES17169301T patent/ES2902418T3/es active Active
- 2011-09-29 PL PL24166417.6T patent/PL4374878T3/pl unknown
- 2011-09-29 NZ NZ609719A patent/NZ609719A/en unknown
- 2011-09-29 DK DK17169328.6T patent/DK3222272T3/da active
- 2011-09-29 KR KR1020137010256A patent/KR101919119B1/ko active Active
- 2011-09-29 PL PL17169328T patent/PL3222272T3/pl unknown
- 2011-09-29 TW TW104135836A patent/TWI661834B/zh active
- 2011-09-29 SI SI201131272T patent/SI2621468T1/sl unknown
- 2011-09-29 BR BR122021001123-0A patent/BR122021001123B1/pt active IP Right Grant
- 2011-09-29 TW TW100135257A patent/TWI532507B/zh active
- 2011-09-29 PT PT241664176T patent/PT4374878T/pt unknown
- 2011-09-29 LT LTEP17169328.6T patent/LT3222272T/lt unknown
- 2011-09-29 PL PL11776530T patent/PL2621468T3/pl unknown
- 2011-09-29 ES ES24166417T patent/ES3027637T3/es active Active
- 2011-09-29 DK DK11776530.5T patent/DK2621468T3/en active
- 2011-09-29 SI SI201132035T patent/SI3246018T1/sl unknown
- 2011-09-29 SM SM20170420T patent/SMT201700420T1/it unknown
- 2011-09-29 PT PT171693013T patent/PT3246018T/pt unknown
- 2011-09-29 MX MX2016014747A patent/MX395271B/es unknown
- 2011-09-29 RU RU2016143751A patent/RU2737264C2/ru active
- 2011-09-29 TW TW106115818A patent/TWI680773B/zh active
- 2011-09-29 PT PT117765305T patent/PT2621468T/pt unknown
- 2011-09-29 HU HUE11776530A patent/HUE034367T2/en unknown
- 2011-09-29 ES ES17169328T patent/ES2905561T3/es active Active
- 2011-09-29 HR HRP20211969TT patent/HRP20211969T1/hr unknown
- 2011-09-29 SI SI201132130T patent/SI4374878T1/sl unknown
- 2011-09-29 RU RU2013112666/15A patent/RU2604690C2/ru active
- 2011-09-29 FI FIEP24166417.6T patent/FI4374878T3/fi active
- 2011-09-29 RS RS20250410A patent/RS66759B1/sr unknown
- 2011-09-29 LT LTEP11776530.5T patent/LT2621468T/lt unknown
- 2011-09-29 PL PL17169301T patent/PL3246018T3/pl unknown
- 2011-09-29 HR HRP20171256TT patent/HRP20171256T1/hr unknown
- 2011-09-29 TW TW108110519A patent/TWI746951B/zh active
- 2011-09-29 HR HRP20250382TT patent/HRP20250382T1/hr unknown
- 2011-09-29 HU HUE24166417A patent/HUE070972T2/hu unknown
- 2011-09-29 US US13/824,132 patent/US9566311B2/en active Active
- 2011-09-29 KR KR1020187032634A patent/KR102102664B1/ko active Active
- 2011-09-29 CN CN201610930206.3A patent/CN107080832B/zh active Active
- 2011-09-29 CN CN201610930541.3A patent/CN107412728A/zh active Pending
- 2011-09-29 EP EP17169301.3A patent/EP3246018B1/en active Active
- 2011-09-29 SM SM20250165T patent/SMT202500165T1/it unknown
- 2011-09-29 HU HUE17169301A patent/HUE057187T2/hu unknown
-
2013
- 2013-03-14 IL IL225238A patent/IL225238B/en active IP Right Grant
-
2016
- 2016-04-27 IL IL245328A patent/IL245328B/en unknown
- 2016-04-27 IL IL245326A patent/IL245326B/en active IP Right Grant
- 2016-11-02 JP JP2016215212A patent/JP6250770B2/ja active Active
- 2016-12-28 US US15/393,053 patent/US20170106044A1/en not_active Abandoned
- 2016-12-28 US US15/393,026 patent/US20170106043A1/en not_active Abandoned
-
2017
- 2017-08-23 CY CY20171100893T patent/CY1119245T1/el unknown
-
2018
- 2018-11-12 JO JOP/2018/0102A patent/JOP20180102B1/ar active
- 2018-11-12 JO JOP/2018/0103A patent/JOP20180103B1/ar active
-
2022
- 2022-02-01 CY CY20221100079T patent/CY1124924T1/el unknown
- 2022-07-12 US US17/863,319 patent/US20230124105A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013543492A5 (enExample) | ||
| US20170360982A1 (en) | Wound Healing Composition Involving Mineral Ions and Methylglyoxal, and Methods of Use | |
| FI4374878T3 (fi) | Karbetosiinia käsittävä farmaseuttinen koostumus | |
| HRP20140716T1 (hr) | Analozi oksitocina | |
| ES2988617T3 (es) | Norketotifeno para el tratamiento de la hipercitocinemia y las infecciones virales | |
| HRP20180007T1 (hr) | Formulacija koja sadrži gemcitabin-predlijek | |
| JP2011502968A5 (enExample) | ||
| ES2664951T5 (es) | Composiciones que comprenden glicosaminoglicanos de baja viscosidad y uso de dicha composición en terapia de cistitis crónica | |
| JP2011225596A5 (enExample) | ||
| JP2022050545A (ja) | 敗血症を処置するための方法および組成物 | |
| JP2015512386A5 (enExample) | ||
| CN106163539A (zh) | 用于预防性传播感染的组合产品 | |
| MX390101B (es) | Tratamiento medico que comprende administracion enteral de edaravona | |
| HK1203394A1 (en) | Ghrelin receptor agonists for the treatment of achlorhydria | |
| HRP20211696T1 (hr) | Postupak izrade fluoriranih olefina | |
| RU2015145451A (ru) | Препараты для местного применения, содержащие гиалуроновую кислоту, вербаскозид и глицерофосфоинозитол | |
| RU2018125252A (ru) | Синергическая комбинация пирролидонкарбоновой кислоты и/или ее солей и гиалуроновой кислоты и/или ее солей для применения в лечении и/или профилактике сухости и раздражения слизистых оболочек, и связанные фармацевтические композиции | |
| RU2011134414A (ru) | Комбинация фульвовой кислоты для лечения различных состояний и болезней | |
| RU2017100906A (ru) | Ретосибан для лечения преждевременных родов | |
| RU2418597C1 (ru) | Способ лечения хронического тонзиллита | |
| JP2011513356A (ja) | 併用療法 | |
| RU2010136277A (ru) | Галеновая форма для трансмукозально-буккального введения триптанов | |
| RU2466746C1 (ru) | Способ лечения больных бесплодием, обусловленным непроходимостью маточных труб и ановуляторным менструальным циклом | |
| RU2016145411A (ru) | Комбинация брекспипразола и налмефена, и ее применение для лечения синдрома химической зависимости | |
| RU2486912C1 (ru) | Средство для спринцевания влагалища в первую фазу лечения кандидозного кольпита (молочницы) |